A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program
Phase of Trial: Phase III
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Adverse reactions
- Acronyms SPRING
- Sponsors Santen Inc
- 19 Sep 2019 Poland is one of the planned location as per European Clinical Trials Database record
- 24 Sep 2018 Status changed from active, no longer recruiting to completed.
- 20 Feb 2018 Trial has been completed in Italy.